| Literature DB >> 30988070 |
Ruolan Bai1,2, Shuijing Chi3, Xiaofei Li4, Xiting Dai3, Zhenhua Ji3, Miaomiao Jian1, Yunfeng Bi3, Feng Wang3, Zhe Ding3, Lisha Luo1, Taigui Chen3, Aihua Liu5,6,7, Fukai Bao8,6,7.
Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) which has been threatening global public health for many years. High genetic diversity is dominant feature of Mtb. Increasing cases of multidrug-resistant (MDR) tuberculosis (MDR-TB) is a serious public health problem to TB control in China. Spontaneous mutations in the Mtb genome can alter proteins which are the target of drugs, making the bacteria drug resistant. The purpose of the present study was to analyze the genotype of Mtb isolates from some areas in Yunnan, China and explore the association between genotypes and MDR-TB. Using spoligotyping, we identified Beijing genotypes, six non-Beijing genotypes and a number of orphan genotypes from 270 Mtb isolates from patients in Yunnan Province during 2014-2016. Of 270 Mtb isolates, 102 clinical Mtb strains were identified as drug-resistant (DR) by drug susceptibility testing (DST), among them, 52 MDR strains. Beijing genotypes occupied the highest MDR proportion (78.85%) followed by the orphan genotypes (15.38%). The characteristics of MDR strains showed high genetic diversity. The results will help to efficiently improve diagnosis and treatment and provide valuable information for Mtb molecular epidemiology.Entities:
Keywords: Mycobacterium tuberculosis; drug susceptibility; genetic diversity; spoligotyping
Mesh:
Year: 2019 PMID: 30988070 PMCID: PMC6542976 DOI: 10.1042/BSR20181746
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Frequencies of genotypes by family in Mtb isolates
| Family | Number (%) of isolates | Number with susceptible isolates (%) | Number with drug-resistance isolates (%) | Number with susceptible isolates/number with MDR isolates | Number with drug-resistance isolates/number with MDR isolates | |
|---|---|---|---|---|---|---|
| Lineage | Sublineage | |||||
| Non-Beijing | 71 (26.30%) | 45 (16.67%) | 26 (9.63%) | 45/11 | 26/11 | |
| H3 | 1 (0.37%) | 1 (0.37%) | 0 | 1/0 | 0/0 | |
| U | 2 (0.74%) | 2 (0.74%) | 0 | 2/0 | 0/0 | |
| MANU2 | 10 (3.70%) | 6 (2.22%) | 4 (1.48%) | 6/1 | 4/0 | |
| T | 20 (7.41%) | 15 (5.56%) | 5 (1.85%) | 15/2 | 5/2 | |
| T1 | 17 (6.30%) | 13 (4.81%) | 4 (1.48%) | 13/2 | 4/2 | |
| T2 | 2 (0.74%) | 2 (0.74%) | 0 | 2/0 | 0/0 | |
| T3 | 1 (0.37%) | 0 | 1 (0.37%) | 0/0 | 0/0 | |
| Orphan | 38 (14.07%) | 21 (7.78%) | 17 (6.30%) | 21/8 | 17/8 | |
| Beijing | 199 (73.70%) | 123 (45.56%) | 76 (28.15%) | 123/41 | 76/41 | |
| Total | 270 | 168 | 102 | 168/52 | 102/52 | |
Characteristics of patients infected with Beijing and non-Beijing isolates of Mtb
| Characteristic | Number (%) of total isolates ( | Number (%) of subgroups of isolates | OR (95% CI) | ||
|---|---|---|---|---|---|
| Beijing, | Non-Beijing, | ||||
| Drug-resistance | 102 (37.8%) | 76 (38.2%) | 26 (36.6%) | 1.069 (0.610–1.874) | 0.815 |
| SM | 39 (14.4%) | 30 (15.1%) | 9 (12.7%) | 1.223 (0.550–2.721) | 0.621 |
| INH | 75 (27.8%) | 57 (28.6%) | 18 (25.4%) | 1.182 (0.638–2.190) | 0.595 |
| RIF | 56 (20.7%) | 44 (22.1%) | 12 (16.9%) | 1.396 (0.689–2.825) | 0.353 |
| EMB | 34 (12.6%) | 27 (13.6%) | 7 (9.9%) | 1.435 (0.596–3.458) | 0.419 |
| PZA | 50 (18.5%) | 40 (20.1%) | 10 (14.1%) | 1.535 (0.723–3.259) | 0.263 |
| MDR (INH+RIF) | 52 (19.3%) | 41 (20.6%) | 11 (15.5%) | 1.597 (0.650–3.926) | 0.305 |
| Men | 164 (60.7%) | 116 (58.3%) | 48 (67.6%) | 1.493 (0.843–2.644) | - |
| Female | 106 (39.3%) | 83 (41.7%) | 23 (32.4%) | 0.168 | |
| >30 | 187 (69.3%) | 135 (67.8%) | 52 (73.2%) | 0.771 (0.421–1.410) | - |
| <30 | 83 (30.7%) | 64 (32.2%) | 19 (26.8%) | 0.397 | |
Abbreviations: CI, confidence interval; OR, odds ratio.
Associations between Beijing strains and drug resistance, stratified by age or sex
| Drug resistance | Age | Total cases, (number) | Beijing genotype, (number) | OR (95% CI) | Sex | Total Cases, (number) | Beijing genotype, (number) | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| SM | >30 | 21 | 14 | 0.776 (0.294–2.047) | Male | 24 | 18 | 1.286 (0.477–3.468) |
| <30 | 18 | 16 | 2.566 (0.535–12.312) | Female | 14 | 12 | 1.775 (0.368–8.565) | |
| INH | >30 | 52 | 37 | 0.931 (0.458–1.893) | Male | 49 | 36 | 0.989 (0.471–2.078) |
| <30 | 23 | 20 | 2.424 (0.634–9.273) | Female | 26 | 21 | 1.219 (0.403–3.691) | |
| RIF | >30 | 38 | 28 | 1.099 (0.491–2.459) | Male | 38 | 28 | 1.209 (0.535–2.735) |
| <30 | 18 | 16 | 2.833 (0.589–13.627) | Female | 18 | 16 | 2.507 (0.532–11.808) | |
| EMB | >30 | 22 | 17 | 1.354 (0.473–3.881) | Male | 21 | 16 | 1.376 (0.474–3.995) |
| <30 | 12 | 10 | 1.574 (0.314–7.899) | Female | 13 | 11 | 1.604 (0.329–7.812) | |
| PZA | >30 | 35 | 25 | 0.955 (0.423–2.156) | Male | 33 | 25 | 1.374 (0.571–3.307) |
| <30 | 15 | 15 | 1.388 (1.197–3.259) | Female | 17 | 15 | 2.316 (0.489–10961) | |
| MDR (INH+RIF) | >30 | 46 | 36 | 1.527 (0.694–3.359) | Male | 35 | 26 | 1.252 (0.537–2.917) |
| <30 | 17 | 16 | 6.000 (0.741–48.59) | Female | 17 | 15 | 2.316 (0.489–10.961) |
Abbreviations: CI, confidence interval; OR, odds ratio.